Fetzima, chemically known as levomilnacipran, received FDA approval on July 2, 2013 [1]. It is indicated for the treatment of major depressive disorder (MDD) in adults [1].
How does Fetzima work?
Fetzima is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) [1]. It functions by increasing the levels of serotonin and norepinephrine in the brain, which are neurotransmitters believed to play a role in mood regulation [2].
What is Fetzima's prescribing information?
Fetzima is available in extended-release capsules [1]. The approved dosage strengths are 40 mg, 80 mg, 120 mg, and 160 mg [1]. Dosing typically starts at 40 mg once daily, with potential increases to 80 mg daily after at least one week. The maximum recommended dose is 160 mg once daily [1]. It should be taken at approximately the same time each day [1].
What are the risks associated with Fetzima?
Like other SNRIs, Fetzima carries a boxed warning regarding suicidal thoughts and behaviors in children, adolescents, and young adults [1][3]. Patients, their families, and caregivers should be advised to monitor for and report any emergence or worsening of depression, unusual changes in behavior, or suicidal thoughts [1]. Other potential serious side effects include increased blood pressure and heart rate, serotonin syndrome, activation of mania or hypomania, angle-closure glaucoma, and hyponatremia [1].
When does Fetzima's patent expire?
Information regarding specific patent expiry dates for Fetzima is available on DrugPatentWatch.com [4].
How does Fetzima compare to other antidepressants?
As an SNRI, Fetzima belongs to a class of antidepressants that includes medications like venlafaxine (Effexor XR) and duloxetine (Cymbalta) [2]. These medications differ in their specific potency and selectivity for serotonin and norepinephrine reuptake, as well as their side effect profiles and approved indications [2]. Levomilnacipran, the active enantiomer of milnacipran, is a more potent norepinephrine reuptake inhibitor compared to its racemic counterpart [2].
What are the alternatives to Fetzima for MDD?
Treatment options for major depressive disorder are diverse and include other antidepressants from various classes, such as selective serotonin reuptake inhibitors (SSRIs), other SNRIs, tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs) [3]. Psychotherapy and other non-pharmacological interventions are also common treatment approaches [3].